Last update 28 Mar 2025

BMS-986442

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
AGEN-1777, AGEN1777, BMS 986442
+ [1]
Action
inhibitors
Mechanism
CD96 inhibitors(CD96 molecule inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
United States
04 Oct 2022
Advanced Malignant Solid NeoplasmPhase 2
Australia
04 Oct 2022
Advanced Malignant Solid NeoplasmPhase 2
Italy
04 Oct 2022
Advanced Malignant Solid NeoplasmPhase 2
Poland
04 Oct 2022
Advanced Malignant Solid NeoplasmPhase 2
Spain
04 Oct 2022
Non-Small Cell Lung CancerPhase 2
United States
04 Oct 2022
Non-Small Cell Lung CancerPhase 2
Australia
04 Oct 2022
Non-Small Cell Lung CancerPhase 2
Italy
04 Oct 2022
Non-Small Cell Lung CancerPhase 2
Poland
04 Oct 2022
Non-Small Cell Lung CancerPhase 2
Spain
04 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
36
(Part A: Treatment 1)
zgaezctpye = ktomayojgx kigtqkunls (mryiccqzgj, zirzahafos - ivmmabkfvk)
-
18 Mar 2025
(Part A: Treatment 2)
zgaezctpye = kwazaqvbfd kigtqkunls (mryiccqzgj, ponrcpohwv - nmnedunwob)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free